Mingxi Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mingxi Tang has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Rui Tang
Department of Pathology, Yaan People’s Hospital
7 shared publicationsLing Jiang
School of Basic Medical Sciences, Southwest Medical University
4 shared publicationsJing Luo
School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan, China
3 shared publicationsLinyan Jiang
Guangzhou Women and Children’s Medical Center, Guangzhou Institute of Pediatrics, Guangzhou Medical University, Guangzhou, China
3 shared publicationsPengyu Miao
School of Basic Medical Sciences, Southwest Medical University
3 shared publicationsTing Tan
Neurobiology Research Center, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China
3 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1983201
Correction: Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice
- 25 September 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1983201
Open AccessCorrection: Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice
- 29 January 2026
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (6) , 1436-1453
Discovery of non-opioid peptides that selectively relieve mechanical pain in rodents through inhibition of TRPV4 channels
Mechanical hyperalgesia is a primary symptom of clinical pain; there remains a therapeutic challenge for severe mechanical and chronic forms of neuropathic pain. The 34-amino-acid neuropeptide GsMTx4, isolated from Tarantula spatulata, was identified as a selective inhibitor of mechanosensitive channels and shown to reduce mechanical hyperalgesia and neuropathic pain in rats. We previously reported two types (type I and type II) of short peptides derived from GsMTx4 that mimicked the inhibitory action of GsMTx4 on a mechanosensitive BK (SAKca) channel. In this study, we investigated whether these short peptides alleviate mechanical hypersensitivity, a major symptom of neuropathic pain. The synthetic type I peptide 01 (Pept 01) was derived from loop2+loop3 of GsMTx4, whereas type II Pept 02, Pept 03 and, Pept 04 were derived from loop 2 of GsMTx4. Carrageenan-induced inflammatory pain was induced in rats and mice, while the chronic constriction nerve injury (CCI) model was established in rats. We showed that administration of short peptides (270 μg/kg, i.p.) selectively inhibited mechanical pain in rats but failed to impact thermal or cold hyperalgesia. Interestingly, the antihyperalgesic effects of these peptides were comparable to those of morphine; however, they were resistant to the μ-opioid receptor antagonist naloxone and lacked morphine-induced side effects, e.g., tolerance and conditioned place preference (CPP). Among them, Pept 03, which contained only one Trp (Trp1) at the head and an additional Arg (Arg11, corresponding to Arg18 in GsMTx4) at the end of the peptide, most potently alleviated mechanical hyperalgesia. Genetic deletion of the TRPV4 gene in mice mostly abolished the analgesic effect of Pept 03. In oocytes expressing TRPV4 channels, application of Pept 03 or Pept 01 inhibited GSK101- or hypotonicity-activated TRPV4 currents in a dose-dependent manner. These results suggest that TRPV4 channels may serve as a direct target for the short peptides in alleviating mechanical pain. This study identifies several natural toxin-based peptides as promising non-opioid analgesics, paving the way for the development of selective and potent painkillers to treat mechanical pain.
- 29 January 2026
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (6) , 1436-1453
Discovery of non-opioid peptides that selectively relieve mechanical pain in rodents through inhibition of TRPV4 channels
Mechanical hyperalgesia is a primary symptom of clinical pain; there remains a therapeutic challenge for severe mechanical and chronic forms of neuropathic pain. The 34-amino-acid neuropeptide GsMTx4, isolated from Tarantula spatulata, was identified as a selective inhibitor of mechanosensitive channels and shown to reduce mechanical hyperalgesia and neuropathic pain in rats. We previously reported two types (type I and type II) of short peptides derived from GsMTx4 that mimicked the inhibitory action of GsMTx4 on a mechanosensitive BK (SAKca) channel. In this study, we investigated whether these short peptides alleviate mechanical hypersensitivity, a major symptom of neuropathic pain. The synthetic type I peptide 01 (Pept 01) was derived from loop2+loop3 of GsMTx4, whereas type II Pept 02, Pept 03 and, Pept 04 were derived from loop 2 of GsMTx4. Carrageenan-induced inflammatory pain was induced in rats and mice, while the chronic constriction nerve injury (CCI) model was established in rats. We showed that administration of short peptides (270 μg/kg, i.p.) selectively inhibited mechanical pain in rats but failed to impact thermal or cold hyperalgesia. Interestingly, the antihyperalgesic effects of these peptides were comparable to those of morphine; however, they were resistant to the μ-opioid receptor antagonist naloxone and lacked morphine-induced side effects, e.g., tolerance and conditioned place preference (CPP). Among them, Pept 03, which contained only one Trp (Trp1) at the head and an additional Arg (Arg11, corresponding to Arg18 in GsMTx4) at the end of the peptide, most potently alleviated mechanical hyperalgesia. Genetic deletion of the TRPV4 gene in mice mostly abolished the analgesic effect of Pept 03. In oocytes expressing TRPV4 channels, application of Pept 03 or Pept 01 inhibited GSK101- or hypotonicity-activated TRPV4 currents in a dose-dependent manner. These results suggest that TRPV4 channels may serve as a direct target for the short peptides in alleviating mechanical pain. This study identifies several natural toxin-based peptides as promising non-opioid analgesics, paving the way for the development of selective and potent painkillers to treat mechanical pain.
- 26 September 2025
- Published by Wiley in Cell Biochemistry and Function
- Vol. 43 (10) , e70124
DNA Methylation Alteration in Early‐Stage of PSEN1/PSEN2 Gene Double Knockout Mouse Models: Integrated Bioinformatics Analysis of Hippocampal Changes Underlying Age‐Related Neurodegeneration
Age‐related neuronal loss is a critical feature of neurodegenerative disorders, including Alzheimer's disease (AD), but its underlying molecular mechanisms, particularly those involving epigenetic regulation, remain incompletely understood. To analyze DNA methylation patterns in early‐stage AD pathogenesis, we employed female presenilin‐1/presenilin‐2 double knockout (PSEN1/PSEN2 dKO, hereafter referred to as dKO) mice as a model system, This animal model have the age‐dependent progressive neurodegenerative changes characteristic of neurodegenerative disorders. Using reduced representation bisulfite sequencing (RRBS), we comprehensively profiled hippocampal DNA methylation patterns in 9‐month‐old dKO mice compared with age‐matched wild‐type controls. Based on RRBS detection results, subsequent bioinformatics analysis through Bismark (v0.7.4) and DAVID v6.8 revealed 1216 differentially methylated sites across multiple chromosomes, corresponding to 796 genes. Through stringent filtering criteria, we identified 50 candidate genes exhibiting significant methylation changes in dKO hippocampal tissue as shown in hierarchical clustering. These genes were functionally enriched in DNA‐dependent transcriptional regulation ( p < 0.01) and protein binding activities ( p < 0.05), with pathway analysis highlighting their involvement in ErbB signaling (FDR = 0.03), melanogenesis (FDR = 0.04), and oncogenic pathways (FDR = 0.05). Our study identifies significant hippocampal DNA methylation changes during the early stages of neurodegeneration in dKO mice. These epigenetic alterations highlight pathways potentially contributing to presenilin‐dependent neuronal loss and suggests potential targets for modulating neurodegeneration linked to presenilin dysfunction.
- 26 September 2025
- Published by Wiley in Cell Biochemistry and Function
- Vol. 43 (10) , e70124
DNA Methylation Alteration in Early‐Stage of PSEN1/PSEN2 Gene Double Knockout Mouse Models: Integrated Bioinformatics Analysis of Hippocampal Changes Underlying Age‐Related Neurodegeneration
Age‐related neuronal loss is a critical feature of neurodegenerative disorders, including Alzheimer's disease (AD), but its underlying molecular mechanisms, particularly those involving epigenetic regulation, remain incompletely understood. To analyze DNA methylation patterns in early‐stage AD pathogenesis, we employed female presenilin‐1/presenilin‐2 double knockout (PSEN1/PSEN2 dKO, hereafter referred to as dKO) mice as a model system, This animal model have the age‐dependent progressive neurodegenerative changes characteristic of neurodegenerative disorders. Using reduced representation bisulfite sequencing (RRBS), we comprehensively profiled hippocampal DNA methylation patterns in 9‐month‐old dKO mice compared with age‐matched wild‐type controls. Based on RRBS detection results, subsequent bioinformatics analysis through Bismark (v0.7.4) and DAVID v6.8 revealed 1216 differentially methylated sites across multiple chromosomes, corresponding to 796 genes. Through stringent filtering criteria, we identified 50 candidate genes exhibiting significant methylation changes in dKO hippocampal tissue as shown in hierarchical clustering. These genes were functionally enriched in DNA‐dependent transcriptional regulation ( p < 0.01) and protein binding activities ( p < 0.05), with pathway analysis highlighting their involvement in ErbB signaling (FDR = 0.03), melanogenesis (FDR = 0.04), and oncogenic pathways (FDR = 0.05). Our study identifies significant hippocampal DNA methylation changes during the early stages of neurodegeneration in dKO mice. These epigenetic alterations highlight pathways potentially contributing to presenilin‐dependent neuronal loss and suggests potential targets for modulating neurodegeneration linked to presenilin dysfunction.
- Open Access
- 12 August 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1560366
Case Report: Breast ductal carcinoma in situ with microinvasion: a case tracked over 13 years
Background: Numerous studies have reported considerable heterogeneity in breast ductal carcinoma in situ with microinvasion (DCIS-MI) regarding clinical presentation, progression potential, and treatment strategies.Case presentation: In this work, we report a case of rapidly progressing multiple metastases in a patient with DCIS-MI following conventional treatment. Subsequent fluorescence in situ hybridization (FISH) testing revealed HER2 gene overexpression. After receiving 10 cycles of trastuzumab-targeted therapy, the patient achieved a favorable prognosis and remains stable to date.Conclusion: This case suggests that even patients with microinvasive lesions who are HER2-positive may exhibit unexpected stability under targeted therapy, warranting close surveillance in such cases.
- 12 August 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1560366
Open AccessCase Report: Breast ductal carcinoma in situ with microinvasion: a case tracked over 13 years
Background: Numerous studies have reported considerable heterogeneity in breast ductal carcinoma in situ with microinvasion (DCIS-MI) regarding clinical presentation, progression potential, and treatment strategies.Case presentation: In this work, we report a case of rapidly progressing multiple metastases in a patient with DCIS-MI following conventional treatment. Subsequent fluorescence in situ hybridization (FISH) testing revealed HER2 gene overexpression. After receiving 10 cycles of trastuzumab-targeted therapy, the patient achieved a favorable prognosis and remains stable to date.Conclusion: This case suggests that even patients with microinvasive lesions who are HER2-positive may exhibit unexpected stability under targeted therapy, warranting close surveillance in such cases.
- Open Access
- 9 June 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1522460
HER2 and hormone receptor conversion after neoadjuvant therapy for breast cancer
Background: The expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in residual lesions may be different compared with primary tumors of the breast after neoadjuvant therapy (NAT). Given the clinical implications of hormone receptor expression for breast cancer management, we assessed conversions in ER, PR, and HER2 in breast cancer patients after NAT.Methods: Our study comprised 589 individuals with aggressive breast cancer who underwent NAT. We examined the ER, PR, and HER2 statuses in primary and residual breast cancers and investigated the relationship between receptor conversion and clinicopathological variables.Results: The pathologic complete response (pCR) rate for the overall cohort was 38.7%, with pCR rates of 57.0%, 13.1%, and 33.3% for HER2-positive, Luminal, and triple-negative breast cancer (TNBC), respectively. Cases with negative hormone receptor expression were more likely to achieve pCR than positive cases. The highest pCR rates were seen in HER2-positive breast cancers, followed by HER2-zero and HER2-low tumors. After NAT, there were 26 (7.8%) cases of ER status conversion and 53 (16.0%) cases of PR status conversion. The conversion of hormone receptors was mainly from positive to negative. When cases were categorized as HER2-negative or positive, 15 (5.1%) cases had a conversion of HER2 status, predominantly positive to negative. When cases were classified as HER2-zero, -low, or -positive, HER2 status conversion happened in 54 (18.6%) cases and was mostly happened between HER2-zero and HER2-low. HER2 status before NAT correlated with ER and HER2 conversion.Conclusion: Some breast cancer patients may show ER, PR, or HER2 status conversion after NAT. Residual lesions need to be immunohistochemically re-tested to reassess the patient’s receptor expression status and to adjust the subsequent treatment regimen.
- 9 June 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1522460
Open AccessHER2 and hormone receptor conversion after neoadjuvant therapy for breast cancer
Background: The expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in residual lesions may be different compared with primary tumors of the breast after neoadjuvant therapy (NAT). Given the clinical implications of hormone receptor expression for breast cancer management, we assessed conversions in ER, PR, and HER2 in breast cancer patients after NAT.Methods: Our study comprised 589 individuals with aggressive breast cancer who underwent NAT. We examined the ER, PR, and HER2 statuses in primary and residual breast cancers and investigated the relationship between receptor conversion and clinicopathological variables.Results: The pathologic complete response (pCR) rate for the overall cohort was 38.7%, with pCR rates of 57.0%, 13.1%, and 33.3% for HER2-positive, Luminal, and triple-negative breast cancer (TNBC), respectively. Cases with negative hormone receptor expression were more likely to achieve pCR than positive cases. The highest pCR rates were seen in HER2-positive breast cancers, followed by HER2-zero and HER2-low tumors. After NAT, there were 26 (7.8%) cases of ER status conversion and 53 (16.0%) cases of PR status conversion. The conversion of hormone receptors was mainly from positive to negative. When cases were categorized as HER2-negative or positive, 15 (5.1%) cases had a conversion of HER2 status, predominantly positive to negative. When cases were classified as HER2-zero, -low, or -positive, HER2 status conversion happened in 54 (18.6%) cases and was mostly happened between HER2-zero and HER2-low. HER2 status before NAT correlated with ER and HER2 conversion.Conclusion: Some breast cancer patients may show ER, PR, or HER2 status conversion after NAT. Residual lesions need to be immunohistochemically re-tested to reassess the patient’s receptor expression status and to adjust the subsequent treatment regimen.
- Open Access
- 30 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1572906
Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice
Background: Resveratrol, a naturally occurring polyphenolic compound found in grapes, berries, and traditional medicinal plants like Polygonum cuspidatum, has been used for centuries in traditional medicine systems for its anti-inflammatory, antioxidant, and cardioprotective properties. Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by intestinal barrier disruption due to excessive colonocyte apoptosis, leading to increased permeability and inflammation. Targeting apoptosis is a critical therapeutic strategy for UC.Aim of the study: This study aims to investigate the therapeutic potential of Resveratrol in ulcerative colitis (UC) by targeting excessive colonocyte apoptosis and intestinal barrier dysfunction. Specifically, we seek to elucidate the mechanisms through which Resveratrol modulates apoptosis-related pathways and evaluate its efficacy in restoring intestinal homeostasis and mitigating UC progression in both in vivo and in vitro models.Materials and Methods: We used dextran sulfate sodium (DSS) to induce UC in a mouse model. Colonic damage was assessed through colonic length measurement, histological examination, and immunofluorescence staining. Single-cell sequencing was employed to explore changes in the colonic immune microenvironment and cellular signaling pathways after Resveratrol treatment. In vitro, colonocytes isolated from healthy mouse colonic tissue were exposed to TGF-β to induce apoptosis. DNA fragmentation, mitochondrial membrane potential, and annexin V/propidium iodide staining were used to assess apoptosis. Additionally, we employed an Adeno-Associated Virus system to overexpress MDM2 in the colon and evaluate its protective role in DSS-induced UC.Results: Resveratrol treatment effectively repaired colonic damage in the UC mouse model by significantly increasing colon length, reducing inflammatory cell infiltration, and mitigating mucosal injury. Single-cell sequencing revealed that Resveratrol primarily targeted colonocytes, decreasing genes related to apoptosis and the P53 pathway. In vitro, Resveratrol reduced DNA fragmentation, apoptotic cell populations, and increased mitochondrial membrane potential in a dose-dependent manner. Furthermore, Resveratrol increased MDM2 expression, inhibiting P53 and downstream pro-apoptotic signaling. Nutlin-3a, an MDM2 inhibitor, reversed the anti-apoptotic effects of Resveratrol. Overexpression of MDM2 in the colon protected against DSS-induced damage.Conclusion: Resveratrol is an effective treatment for DSS-induced UC, primarily by inhibiting excessive apoptosis in colonocytes through the MDM2/P53/PUMA axis. MDM2 presents a promising therapeutic target for UC treatment.
- 30 April 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1572906
Open AccessResveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice
Background: Resveratrol, a naturally occurring polyphenolic compound found in grapes, berries, and traditional medicinal plants like Polygonum cuspidatum, has been used for centuries in traditional medicine systems for its anti-inflammatory, antioxidant, and cardioprotective properties. Ulcerative colitis (UC), a chronic inflammatory bowel disease, is characterized by intestinal barrier disruption due to excessive colonocyte apoptosis, leading to increased permeability and inflammation. Targeting apoptosis is a critical therapeutic strategy for UC.Aim of the study: This study aims to investigate the therapeutic potential of Resveratrol in ulcerative colitis (UC) by targeting excessive colonocyte apoptosis and intestinal barrier dysfunction. Specifically, we seek to elucidate the mechanisms through which Resveratrol modulates apoptosis-related pathways and evaluate its efficacy in restoring intestinal homeostasis and mitigating UC progression in both in vivo and in vitro models.Materials and Methods: We used dextran sulfate sodium (DSS) to induce UC in a mouse model. Colonic damage was assessed through colonic length measurement, histological examination, and immunofluorescence staining. Single-cell sequencing was employed to explore changes in the colonic immune microenvironment and cellular signaling pathways after Resveratrol treatment. In vitro, colonocytes isolated from healthy mouse colonic tissue were exposed to TGF-β to induce apoptosis. DNA fragmentation, mitochondrial membrane potential, and annexin V/propidium iodide staining were used to assess apoptosis. Additionally, we employed an Adeno-Associated Virus system to overexpress MDM2 in the colon and evaluate its protective role in DSS-induced UC.Results: Resveratrol treatment effectively repaired colonic damage in the UC mouse model by significantly increasing colon length, reducing inflammatory cell infiltration, and mitigating mucosal injury. Single-cell sequencing revealed that Resveratrol primarily targeted colonocytes, decreasing genes related to apoptosis and the P53 pathway. In vitro, Resveratrol reduced DNA fragmentation, apoptotic cell populations, and increased mitochondrial membrane potential in a dose-dependent manner. Furthermore, Resveratrol increased MDM2 expression, inhibiting P53 and downstream pro-apoptotic signaling. Nutlin-3a, an MDM2 inhibitor, reversed the anti-apoptotic effects of Resveratrol. Overexpression of MDM2 in the colon protected against DSS-induced damage.Conclusion: Resveratrol is an effective treatment for DSS-induced UC, primarily by inhibiting excessive apoptosis in colonocytes through the MDM2/P53/PUMA axis. MDM2 presents a promising therapeutic target for UC treatment.
- Open Access
- 3 December 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1485657
Neuroimaging techniques, gene therapy, and gut microbiota: frontier advances and integrated applications in Alzheimer’s Disease research
Alzheimer’s Disease (AD) is a neurodegenerative disorder marked by cognitive decline, for which effective treatments remain elusive due to complex pathogenesis. Recent advances in neuroimaging, gene therapy, and gut microbiota research offer new insights and potential intervention strategies. Neuroimaging enables early detection and staging of AD through visualization of biomarkers, aiding diagnosis and tracking of disease progression. Gene therapy presents a promising approach for modifying AD-related genetic expressions, targeting amyloid and tau pathology, and potentially repairing neuronal damage. Furthermore, emerging evidence suggests that the gut microbiota influences AD pathology through the gut-brain axis, impacting inflammation, immune response, and amyloid metabolism. However, each of these technologies faces significant challenges, including concerns about safety, efficacy, and ethical considerations. This article reviews the applications, advantages, and limitations of neuroimaging, gene therapy, and gut microbiota research in AD, with a particular focus on their combined potential for early diagnosis, mechanistic insights, and therapeutic interventions. We propose an integrated approach that leverages these tools to provide a multi-dimensional framework for advancing AD diagnosis, treatment, and prevention.
- 3 December 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 16, 1485657
Open AccessNeuroimaging techniques, gene therapy, and gut microbiota: frontier advances and integrated applications in Alzheimer’s Disease research
Alzheimer’s Disease (AD) is a neurodegenerative disorder marked by cognitive decline, for which effective treatments remain elusive due to complex pathogenesis. Recent advances in neuroimaging, gene therapy, and gut microbiota research offer new insights and potential intervention strategies. Neuroimaging enables early detection and staging of AD through visualization of biomarkers, aiding diagnosis and tracking of disease progression. Gene therapy presents a promising approach for modifying AD-related genetic expressions, targeting amyloid and tau pathology, and potentially repairing neuronal damage. Furthermore, emerging evidence suggests that the gut microbiota influences AD pathology through the gut-brain axis, impacting inflammation, immune response, and amyloid metabolism. However, each of these technologies faces significant challenges, including concerns about safety, efficacy, and ethical considerations. This article reviews the applications, advantages, and limitations of neuroimaging, gene therapy, and gut microbiota research in AD, with a particular focus on their combined potential for early diagnosis, mechanistic insights, and therapeutic interventions. We propose an integrated approach that leverages these tools to provide a multi-dimensional framework for advancing AD diagnosis, treatment, and prevention.
- Open Access
- 2 December 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 289, 117449
The mediating role of accelerated biological aging in the association between household air pollution from solid cooking fuels and neuropsychiatric disorders
- 2 December 2024
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 289, 117449
Open AccessThe mediating role of accelerated biological aging in the association between household air pollution from solid cooking fuels and neuropsychiatric disorders
- Open Access
- 29 September 2024
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 23 (10) , 184
Key Synaptic Pathology in Autism Spectrum Disorder: Genetic Mechanisms and Recent Advances
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interactions and verbal communication, accompanied by symptoms of restricted and repetitive patterns of behavior or interest. Over the past 30 years, the morbidity of ASD has increased in most areas of the world. Although the pathogenesis of ASD is not fully understood, it has been associated with over 1000 genes or genomic loci, indicating the importance and complexity of the genetic mechanisms involved. This review focuses on the synaptic pathology of ASD and particularly on genetic variants involved in synaptic structure and functions. These include SHANK, NLGN, NRXN, FMR1, and MECP2 as well as other potentially novel genes such as CHD8, CHD2, and SYNGAP1 that could be core elements in ASD pathogenesis. Here, we summarize several pathological pathways supporting the hypothesis that synaptic pathology caused by genetic mutations may be the pathogenic basis for ASD.
- 29 September 2024
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 23 (10) , 184
Open AccessKey Synaptic Pathology in Autism Spectrum Disorder: Genetic Mechanisms and Recent Advances
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired social interactions and verbal communication, accompanied by symptoms of restricted and repetitive patterns of behavior or interest. Over the past 30 years, the morbidity of ASD has increased in most areas of the world. Although the pathogenesis of ASD is not fully understood, it has been associated with over 1000 genes or genomic loci, indicating the importance and complexity of the genetic mechanisms involved. This review focuses on the synaptic pathology of ASD and particularly on genetic variants involved in synaptic structure and functions. These include SHANK, NLGN, NRXN, FMR1, and MECP2 as well as other potentially novel genes such as CHD8, CHD2, and SYNGAP1 that could be core elements in ASD pathogenesis. Here, we summarize several pathological pathways supporting the hypothesis that synaptic pathology caused by genetic mutations may be the pathogenic basis for ASD.
- Open Access
- 20 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 9036
A Bioinformatics-Based Study on Methylation Alterations of the FBLN1 Gene in Hippocampal Tissue of Alzheimer’s Disease Model DKO and DTG Mice
Alzheimer’s disease (AD) is characterized by progressive cognitive decline and late-stage neurobehavioral issues marked by amyloid-beta plaques and Tau protein tangles. This study aims to investigate Fibulin-1(FBLN1) gene expression in the hippocampal tissue of Presenilin-1/Presenilin-2 conditional double-knockout (DKO) and double-transgenic (DTG) mice, using single-cell sequencing and experimental methods to verify abnormal methylation status and correlation with AD. Genomic DNA from DKO and DTG mice was used for genotyping. Reduced Representation Bisulfite Sequencing (RRBS) identified 10 genes with abnormal methylation changes, with protein–protein interaction (PPI) analysis highlighting five core genes, including FBLN1. Single-cell sequencing, RT-PCR, and Western blotting (WB) were used to analyze FBLN1 mRNA and protein levels in the hippocampal tissues of early-stage and mid-stage AD DKO, DTG, and CBAC57 mice. RRBS identified 10 genes with abnormal methylation, with PPI highlighting five core genes. Single-cell sequencing showed significant FBLN1 expression in AD groups. RT-PCR and WB indicated elevated FBLN1 mRNA and protein levels in mid-stage AD DKO and DTG mice compared to CBAC57 mice, with no differences in early-stage AD DKO and CBAC57 mice. RRBS revealed hypomethylation of the FBLN1 gene in mid-stage AD DKO mice. Elevated FBLN1 expression in AD models suggests an age-dependent neurodegenerative mechanism independent of amyloid-beta deposition. This study enhances our understanding of AD’s epigenetic mechanisms, which will aid targeted diagnosis, treatment, and prognosis.
- 20 August 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 9036
Open AccessA Bioinformatics-Based Study on Methylation Alterations of the FBLN1 Gene in Hippocampal Tissue of Alzheimer’s Disease Model DKO and DTG Mice
Alzheimer’s disease (AD) is characterized by progressive cognitive decline and late-stage neurobehavioral issues marked by amyloid-beta plaques and Tau protein tangles. This study aims to investigate Fibulin-1(FBLN1) gene expression in the hippocampal tissue of Presenilin-1/Presenilin-2 conditional double-knockout (DKO) and double-transgenic (DTG) mice, using single-cell sequencing and experimental methods to verify abnormal methylation status and correlation with AD. Genomic DNA from DKO and DTG mice was used for genotyping. Reduced Representation Bisulfite Sequencing (RRBS) identified 10 genes with abnormal methylation changes, with protein–protein interaction (PPI) analysis highlighting five core genes, including FBLN1. Single-cell sequencing, RT-PCR, and Western blotting (WB) were used to analyze FBLN1 mRNA and protein levels in the hippocampal tissues of early-stage and mid-stage AD DKO, DTG, and CBAC57 mice. RRBS identified 10 genes with abnormal methylation, with PPI highlighting five core genes. Single-cell sequencing showed significant FBLN1 expression in AD groups. RT-PCR and WB indicated elevated FBLN1 mRNA and protein levels in mid-stage AD DKO and DTG mice compared to CBAC57 mice, with no differences in early-stage AD DKO and CBAC57 mice. RRBS revealed hypomethylation of the FBLN1 gene in mid-stage AD DKO mice. Elevated FBLN1 expression in AD models suggests an age-dependent neurodegenerative mechanism independent of amyloid-beta deposition. This study enhances our understanding of AD’s epigenetic mechanisms, which will aid targeted diagnosis, treatment, and prognosis.